98. Bourgeois-Nicolaos N, Massias L, Couson B, Butel MJ, Andremont A, Doucet-Populaire F. Dose depend- ence of emergence of resistance to linezolid in Enterococcus faecalis in vivo. J Infect Dis 2007; 195: 1480-8; PMID:17436228; http://dx.doi.org/10.1086/ 513876 99. Biedenbach DJ, Farrell DJ, Mendes RE, Ross JE, Jones RN. Stability of linezolid activity in an era of mobile oxazolidinone resistance determinants: results from the 2009 Zyvox1 Annual Appraisal of Potency and Spectrum program. Diagn Microbiol Infect Dis 2010; 68:459-67; PMID:21094428; http://dx.doi. org/10.1016/j.diagmicrobio.2010.09.018 100. Prystowsky J, Siddiqui F, Chosay J, Shinabarger DL, Millichap J, Peterson LR, et al. Resistance to linezolid: characterization of mutations in rRNA and comparison of their occurrences in vancomycin-resistant entero- cocci. Antimicrob Agents Chemother 2001; 45:2154- 6; PMID:11408243; http://dx.doi.org/10.1128/AAC. 45.7.2154-2156.2001 101. Long KS, Poehlsgaard J, Kehrenberg C, Schwarz S, Vester B. The Cfr rRNA methyltransferase confers resistance to Phenicols, Lincosamides, Oxazolidinones, Pleuromutilins, and Streptogramin A antibiotics. Antimicrob Agents Chemother 2006; 50:2500-5; PMID:16801432; http://dx.doi.org/10.1128/AAC. 00131-06 102. Toh SM, Xiong L, Arias CA, Villegas MV, Lolans K, Quinn J, et al. Acquisition of a natural resistance gene renders a clinical strain of methicillin-resistant Staphylococcus aureus resistant to the synthetic antibiotic linezolid. Mol Microbiol 2007; 64:1506- 14; PMID:17555436; http://dx.doi.org/10.1111/j. 1365-2958.2007.05744.x 103. Liu Y, Wang Y, Wu C, Shen Z, Schwarz S, Du X, et al. First Report of the Multidrug Resistance gene cfr in Enterococcus faecalis of Animal origin. Antimicrob Agents Chemother 2012; 56:1650-4; PMID: 22203597; http://dx.doi.org/10.1128/AAC.06091-11 104. Cantón R, Ruiz-Garbajosa P, Chaves RL, Johnson AP. A potential role for daptomycin in enterococcal infections: what is the evidence? J Antimicrob Chemother 2010; 65:1126-36; PMID:20363805; http://dx.doi.org/10.1093/jac/dkq087 105. Crank CW, Scheetz MH, Brielmaier B, Rose WE, Patel GP, Ritchie DJ, et al. Comparison of outcomes from daptomycin or linezolid treatment for vancomy- cin-resistant enterococcal bloodstream infection: A retrospective, multicenter, cohort study. Clin Ther 2010; 32:1713-9; PMID:21194593; http://dx.doi.org/ 10.1016/j.clinthera.2010.09.008 106. Poutsiaka DD, Skiffington S, Miller KB, Hadley S, Snydman DR. Daptomycin in the treatment of vancomycin-resistant Enterococcus faecium bacteremia in neutropenic patients. J Infect 2007; 54:567-71; PMID:17188750; http://dx.doi.org/10.1016/j.jinf. 2006.11.007 107. Kelesidis T, Humphries R, Uslan DZ, Pegues DA. Daptomycin nonsusceptible enterococci: an emerging challenge for clinicians. Clin Infect Dis 2011; 52:228- 34; PMID:21288849; http://dx.doi.org/10.1093/cid/ ciq113 108. Lakey JH, Ptak M. Fluorescence indicates a calcium- dependent interaction between the lipopeptide anti- biotic LY146032 and phospholipid membranes. Biochemistry 1988; 27:4639-45; PMID:2844233; http://dx.doi.org/10.1021/bi00413a009 109. Alborn WE, Jr., Allen NE, Preston DA. Daptomycin disrupts membrane potential in growing Staphylococcus aureus. Antimicrob Agents Chemother 1991; 35:2282-7; PMID:1666494 110. Silverman JA, Perlmutter NG, Shapiro HM. Correlation of daptomycin bactericidal activity and membrane depolarization in Staphylococcus aureus. Antimicrob Agents Chemother 2003; 47:2538-44; PMID:12878516; http://dx.doi.org/10.1128/AAC.47. 8.2538-2544.2003 111. Silverman JA, Oliver N, Andrew T, Li T. Resistance studies with daptomycin. Antimicrob Agents Chemother 2001; 45:1799-802; PMID:11353628; http://dx.doi.org/10.1128/AAC.45.6.1799-1802.2001 112. Friedman L, Alder JD, Silverman JA. Genetic changes that correlate with reduced susceptibility to daptomy- cin in Staphylococcus aureus. Antimicrob Agents Chemother 2006; 50:2137-45; PMID:16723576; http://dx.doi.org/10.1128/AAC.00039-06 113. Palmer KL, Daniel A, Hardy C, Silverman J, Gilmore MS. Genetic basis for daptomycin resistance in enterococci. Antimicrob Agents Chemother 2011; 55:3345-56; PMID:21502617; http://dx.doi.org/10. 1128/AAC.00207-11 114. Arias CA, Panesso D, McGrath DM, Qin X, Mojica MF, Miller C, et al. Genetic basis for in vivo daptomycin resistance in enterococci. N Engl J Med 2011; 365:892-900; PMID:21899450; http://dx.doi. org/10.1056/NEJMoa1011138 115. Cai Y, Wang R, Liang B, Bai N, Liu Y. Systematic review and meta-analysis of the effectiveness and safety of tigecycline for treatment of infectious disease. Antimicrob Agents Chemother 2011; 55:1162-72; PMID:21173186; http://dx.doi.org/10.1128/AAC. 01402-10 116. Kresken M, Leitner E, Seifert H, Peters G, von Eiff C. Susceptibility of clinical isolates of frequently encoun- tered bacterial species to tigecycline one year after the introduction of this new class of antibiotics: results of the second multicentre surveillance trial in Germany (G-TEST II, 2007). Eur J Clin Microbiol Infect Dis 2009; 28:1007-11; PMID:19296137; http://dx.doi. org/10.1007/s10096-009-0725-5 117. Werner G, Gfrörer S, Fleige C, Witte W, Klare I. Tigecycline-resistant Enterococcus faecalis strain iso- lated from a German intensive care unit patient. J Antimicrob Chemother 2008; 61:1182-3; PMID: 18285315; http://dx.doi.org/10.1093/jac/dkn065 118. Cordina C, Hill R, Deshpande A, Hood J, Inkster T. Tigecycline-resistant Enterococcus faecalis associated with omeprazole use in a surgical patient. J Antimicrob Chemother 2012; 67:1806-7; PMID:22454491; http://dx.doi.org/10.1093/jac/dks122 119. Tsai HY, Liao CH, Chen YH, Lu PL, Huang CH, Lu CT, et al. Trends in susceptibility of vancomycin- resistant Enterococcus faecium to tigecycline, dapto- mycin, and linezolid and molecular epidemiology of the isolates: results from the Tigecycline In Vitro Surveillance in Taiwan (TIST) study, 2006 to 2010. Antimicrob Agents Chemother 2012; 56:3402-5; PMID:22491684; http://dx.doi.org/10.1128/AAC. 00533-12 120. McAleese F, Petersen P, Ruzin A, Dunman PM, Murphy E, Projan SJ, et al. A novel MATE family efflux pump contributes to the reduced susceptibility of laboratory-derived Staphylococcus aureus mutants to tigecycline. Antimicrob Agents Chemother 2005; 49:1865-71; PMID:15855508; http://dx.doi.org/10. 1128/AAC.49.5.1865-1871.2005 121. Francioli P, Ruch W, Stamboulian D. Treatment of streptococcal endocarditis with a single daily dose of ceftriaxone and netilmicin for 14 days: a prospective multicenter study. Clin Infect Dis 1995; 21:1406-10; PMID:8749624; http://dx.doi.org/10.1093/clinids/ 21.6.1406 122. Gavaldà J, Cardona PJ, Almirante B, Capdevila JA, Laguarda M, Pou L, et al. Treatment of experimental endocarditis due to Enterococcus faecalis using once- daily dosing regimen of gentamicin plus simulated profiles of ampicillin in human serum. Antimicrob Agents Chemother 1996; 40:173-8; PMID:8787901 123. Houlihan HH, Stokes DP, Rybak MJ. Pharmacodynamics of vancomycin and ampicillin alone and in combination with gentamicin once daily or thrice daily against Enterococcus faecalis in an in vitro infection model. J Antimicrob Chemother 2000; 46:79-86; PMID:10882693; http://dx.doi.org/10. 1093/jac/46.1.79 124. López P, Gavaldà J, Martin MT, Almirante B, Gomis X, Azuaje C, et al. Efficacy of teicoplanin-gentamicin given once a day on the basis of pharmacokinetics in humans for treatment of enterococcal experimental endocarditis. Antimicrob Agents Chemother 2001; 45: 1387-93; PMID:11302800; http://dx.doi.org/10. 1128/AAC.45.5.1387-1393.2001 125. Fantin B, Carbon C. Importance of the aminoglyco- side dosing regimen in the penicillin-netilmicin combination for treatment of Enterococcus faecalis- induced experimental endocarditis. Antimicrob Agents Chemother 1990; 34:2387-91; PMID:2128443 126. Marangos MN, Nicolau DP, Quintiliani R, Nightingale CH. Influence of gentamicin dosing interval on the efficacy of penicillin-containing regimens in experi- mental Enterococcus faecalis endocarditis. J Antimicrob Chemother 1997; 39:519-22; PMID: 9145826; http://dx.doi.org/10.1093/jac/39.4.519 127. Baddour LM, Wilson WR, Bayer AS, Fowler VG, Jr., Bolger AF, Levison ME, et al, Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, Councils on Clinical Cardiology, Stroke, and Cardiovascular Surgery and Anesthesia, American Heart Association, Infectious Diseases Society of America. Infective endocarditis: diagnosis, antimicro- bial therapy, and management of complications: a statement for healthcare professionals from the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, and the Councils on Clinical Cardiology, Stroke, and Cardiovascular Surgery and Anesthesia, American Heart Association: endorsed by the Infectious Diseases Society of America. Circulation 2005; 111:e394-434; PMID:15956145; http://dx.doi. org/10.1161/CIRCULATIONAHA.105.165564 128. Furustrand Tafin U, Majic I, Zalila Belkhodja C, Betrisey B, Corvec S, Zimmerli W, et al. Gentamicin improves the activities of daptomycin and vancomycin against Enterococcus faecalis in vitro and in an experimental foreign-body infection model. Antimicrob Agents Chemother 2011; 55:4821-7; PMID:21807979; http://dx.doi.org/10.1128/AAC.00141-11 129. Gavaldá J, Onrubia PL, Gómez MT, Gomis X, Ramírez JL, Len O, et al. Efficacy of ampicillin combined with ceftriaxone and gentamicin in the treatment of experimental endocarditis due to Enterococcus faecalis with no high-level resistance to aminoglycosides. J Antimicrob Chemother 2003; 52: 514-7; PMID:12917251; http://dx.doi.org/10.1093/ jac/dkg360 432 Virulence Volume 3 Issue 5